Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Efficacy of eprosartan in combination with HCTZ in patients with essential hypertension

Journal of Human Hypertension volume 16, pages 169–176 (2002)Cite this article

Abstract

This randomised, double-blind study was designed to investigate the efficacy of a once-daily (OD) combination of the AT1 receptor blocker, eprosartan 600 mg, and the thiazide diuretic, hydrochlorothiazide (HCTZ) 12.5 mg, in patients with mild to moderate hypertension (sitting diastolic blood pressure (sitDBP) ⩾98 mm Hg and ⩽114 mm Hg) not adequately controlled with eprosartan 600 mg OD. A total of 494 patients entered the open-label monotherapy run-in phase, which consisted of eprosartan 600 mg OD for 3 weeks. Patients who responded to monotherapy were not eligible to enter the randomised phase of the study and were withdrawn. The remaining 309 patients were then randomised to either eprosartan 600 mg plus HCTZ 12.5 mg OD or to continue on eprosartan 600 mg OD. In the eprosartan plus HCTZ combination group, both sitDBP and sitting systolic blood pressure (sitSBP) were significantly reduced compared with the eprosartan monotherapy group. In addition, the response rate was higher in the combination group compared with the monotherapy group. There were no significant effects on reduction of sitDBP due to gender, prior use of antihypertensives or baseline severity of hypertension. The tolerability profile for the combination group was similar to that for the monotherapy group. Headache was the most frequent adverse event in both treatment groups. The majority of adverse events were mild to moderate in intensity. In this study of patients who were unresponsive to eprosartan monotherapy for 3 weeks, a combination product of eprosartan 600 mg and HCTZ 12.5 mg was shown to be an effective and well tolerated treatment.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Materson BJ, Preston RA . Angiotensin-converting enzyme inhibitors in hypertension: a dozen years of experience Arch Intern Med 1994 154: 513–523

    Article  CAS  Google Scholar 

  2. Hedner T et al. Dyspnoea, asthma, and bronchospasm in relation to treatment with angiotensin converting enzyme inhibitors BMJ 1992 304: 941–946

    Article  CAS  Google Scholar 

  3. Nishimura H et al. Angiotensin converting enzyme and chymase in cardiovascular tissues Kidney Int 1996 49: S18–S23

    Google Scholar 

  4. Gradman AH et al. Assessment of once-daily eprosartan, an angiotensin II antagonist, inpatients with systemic hypertension Clin Therapeut 1999 21: 442–453

    Article  CAS  Google Scholar 

  5. Hedner T, Himmelmann A for the Eprosartan Multinational Study Group. The efficacy and tolerance of one and two daily doses of eprosartan in essential hypertension J Hypertens 1999 17: 129–136

    Article  CAS  Google Scholar 

  6. Sega R et al. Efficacy and safety of eprosartan in severe hypertension Blood Press 1999 8: 114–121

    Article  CAS  Google Scholar 

  7. Gavras I, Gavras H . Effects of eprosartan versus enalapril in hypertensivepatients on the renin-angiotensin-aldosterone system and safety parameters: results from a 26-week, double-blind, multicentre study Curr Med Res Opin 1999 15: 15–24

    Article  CAS  Google Scholar 

  8. Weber M . Clinical efficacy of eprosartan Pharmacotherapy 1999 19: 95S–101S

    Article  CAS  Google Scholar 

  9. Neutel JM, Black HR, Weber MA . Combination therapy with diuretics: an evolution of understanding Am J Med 1996 101: 61S–70S

    Article  CAS  Google Scholar 

  10. McVeigh GE, Flack J, Grimm R . Goals of antihypertensive therapy Drugs 1995 49: 161–175

    Article  CAS  Google Scholar 

  11. Plat F, Saini R . Management of hypertension – the role of combination therapy Am J Hypertens 1997 10: 262S–271S

    Article  CAS  Google Scholar 

  12. Langtry H, McClellan K . Valsartan/hydrochloro-thiazide Drugs 1999 57: 751–758

    Article  CAS  Google Scholar 

  13. Elliott WJ . Double-blind comparison of eprosartan and enalapril on cough and blood pressure in unselected hypertensivepatients J Hum Hypertens 1999 13: 413–417

    Article  CAS  Google Scholar 

  14. Levine B . Eprosartan provides safe and long-term maintenance of blood pressure control inpatients with mild to moderate hypertension Curr Med Res Opin 2001 17: 8–17

    Article  CAS  Google Scholar 

  15. Hedner T . Long-term safety and tolerability of once-daily eprosartan inpatients with essential hypertension In preparation

  16. Mackay JH et al. Losartan and low dose hydrochlorothiazide inpatients with essential hypertension Arch Intern Med 1996 156: 278–285

    Article  CAS  Google Scholar 

  17. Chrysant SG, Wombolt DG, Feliciano N, Zheng H . Long-term efficacy, safety, and tolerability of valsartan and hydrochlorothiazide inpatients with essential hypertension Curr Ther Res 1998 59: 762–771

    Article  CAS  Google Scholar 

  18. Alper AB Jr, Calhoun . Contemporary management of refractory hypertension Curr Hypertens Rep 1999 1: 402–407

    Article  Google Scholar 

Download references

Acknowledgements

This trial was performed at the following centres:

Belgium: Creytens GJJ, Dufour AGR, Borschette C, Narcisse D, Kivits A, van Esch C.

France: Farhaf S, Pithon M, Gabriello JL, Willman J-F, Mascherpa E, Fonteny R, Blaignan J, Giner M, Lalanue G, Voiriot P, Letzelter J-M, Sicard J, Campagne A, Cadinot D, Etchegaray G, Boye A, Lejay D, Boucher L.

Ireland: Bradbury FN, Forde D, McGarry P, Sullivan J, Belton M, O'Doherty BP.

Author information

Authors and Affiliations

  1. Solvay Pharmaceuticals, Hans Böckler Allee 20, Hannover, D-30173, Germany

    A Sachse, C N Verboom & B Jäger

Authors
  1. A Sachse
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C N Verboom
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. B Jäger
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A Sachse.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sachse, A., Verboom, C. & Jäger, B. Efficacy of eprosartan in combination with HCTZ in patients with essential hypertension. J Hum Hypertens 16, 169–176 (2002). https://doi.org/10.1038/sj.jhh.1001317

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.jhh.1001317

Keywords

This article is cited by

Search

Advanced search

Quick links